bronchiectasis
BRONCHIECTASIS
Bronchiectasis is an irreversible pathologic dilatation or ectasia of the bronchi due to repeated airway infection and inflammation.
It enhances susceptibility to bronchial infection and increases inflammatory reaction which causes further lung damage.
Classic symptoms of of bronchiectasis are cough with chronic sputum production along with recurring infective exacerbations and hemoptysis.

Supportive Therapy

Specific Therapy for Individual Causes
Hypogammaglobulinemia
  • Administer IV immunoglobulins w/ guidance & supervision from an immunologist
Primary Ciliary Dyskinesia
  • More intensive therapy based on the assumption that disease progression is more likely
  • Emphasis on physical therapy
TB, HIV, Rheumatoid arthritis, Sarcoidosis
  • Treat active associated disease
  • Bronchiectasis may precede, accompany or follow the development of associated disease
Allergic Bronchopulmonary Aspergillosis (ABPA)
  • Control of asthma & prevention of damage from acute exacerbations of ABPA
  • Consider maintenance oral corticosteroids
  • Antifungal therapy remains 2nd-line choice, unless there is associated invasive Aspergillosis
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
15 Aug 2017
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
04 Aug 2017
Chronic obstructive pulmonary disease (COPD) is the fourth cause of global mortality, with experts predicting a potential future rise in the prevalence rates of COPD. 
11 May 2016

In conjunction with World Asthma Day which falls on 3rd May 2016, MIMS Doctor speaks to a renowned respiratory medicine specialist, Dato' Dr. Hj Abdul Razak Abdul Muttalif, regarding the chronic airway disease.

Pearl Toh, 22 May 2016
Asthma patients on salmeterol, a long-acting beta-agonist (LABA), plus fluticasone inhaled corticosteroid (ICS) combination therapy did not have a greater risk of serious asthma-related events compared with patients receiving fluticasone alone, according to the recent AUSTRI* study.